Pyxis Oncology Inc expected to post a loss of 29 cents a share - Earnings Preview

Pyxis Oncology

09/05/2025 16:13

Pyxis Oncology Inc PYXS.OQ PYXS.O is expected to show a fall in quarterly revenue when it reports  results on May 12 (estimated) for the period ending March 31 2025

​LSEG's mean analyst estimate for Pyxis Oncology Inc is for a loss of 29 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Pyxis Oncology Inc is $6.00​, above​ its last closing price of $1.09. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.34
-0.33
-0.25
Beat
24.2
Sep. 30 2024
-0.31
-0.31
-0.35
Missed
-11.7
Jun. 30 2024
-0.32
-0.32
-0.29
Beat
10.6​
Mar. 31 2024
-0.21
-0.24
-0.06
Beat
75.2
​​Dec. 31 2023
-0.48
-0.47
-0.33
Beat
30.5
Sep. 30 2023
-0.49
-0.51
-0.56
Missed
-10.5​
Jun. 30 2023
-0.64
-0.65
-0.41
Beat
36.7
Mar. 31 2023
-0.90
-0.90
-0.55
Beat
38.8

This summary was machine generated May 9 at 15:13 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)